Observational studyJournal of neuro-oncology2017
Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base.
Observational study in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.Radiation oncology (London, England) · 2017Trial
- Cationic Micelle-like Nanoparticles as the Carrier of Methotrexate for Glioblastoma Treatment.Molecules (Basel, Switzerland) · 2024Article
- Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models.Cancers · 2024Review
- Prognostic nomogram models for predicting survival probability in elderly glioblastoma patients.Journal of cancer research and clinical oncology · 2023Article
- A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.Cellular and molecular neurobiology · 2022Article
- Therapeutic efficacy ofFrontiers in oncology · 2022Article
- The Value of H2BC12 for Predicting Poor Survival Outcomes in Patients With WHO Grade II and III Gliomas.Frontiers in molecular biosciences · 2022Article
- Mir-139-5p inhibits glioma cell proliferation and progression by targeting GABRA1.Journal of translational medicine · 2021Article
- Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma.Scientific reports · 2021Article
- ＜Editors' Choice＞ Impact of maintenance of postoperative performance status on survival in elderly patients over 70 with high-grade astrocytoma.Nagoya journal of medical science · 2020Article
- Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study.Neuro-oncology advances · 2020Article
- An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.Frontiers in immunology · 2020Article
- The Misclassification of Diffuse Gliomas: Rates and Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- National cancer database analysis of outcomes in pediatric glioblastoma.Cancer medicine · 2018Article
- Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?Journal of neuro-oncology · 2017Article
- Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume.Journal of neuro-oncology · 2017Article
- Geographic Variations in the Incidence of Glioblastoma and Prognostic Factors Predictive of Overall Survival in US Adults from 2004-2013.Frontiers in aging neuroscience · 2017Article
- Neuro-oncology: a selected review of ASCO 2016 abstracts.CNS oncology · 2016Article
- Cytotoxic effects of auraptene against a human malignant glioblastoma cell line.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the utilization and overall survival (OS) impact of concurrent chemotherapy in combination with radiation therapy (RT) for elderly glioblastoma (GBM) patients. Elderly patients (age >70) with supratentorial and nonmetastatic GBM who received RT of 20-75 Gy with concurrent single-agent chemotherapy (ChemoRT) or without (RT alone) during 2004-2012 were identified from the National Cancer Data Base (NCDB). The Cochran-Armitage test was used for trend analysis. Hazard ratios (HR) and 95% confidence intervals (CIs) were determined using Cox proportional hazards. Propensity score analysis was performed to reduce selection bias in treatment allocation. A total of 5252 patients were identified (RT alone: n = 1389; ChemoRT: n = 3863). There was increasing utilization of chemotherapy during this period (45-80%, P < .001). A similar trend was also observed for the subset of age >80 (25-68%, P < .001). ChemoRT was associated with significantly better OS than RT alone (HR 0.79, 95% CI 0.70-0.89, P < .001) on multivariate analysis, and similar OS benefit was demonstrated with 1202 pairs of propensity-matched patients (HR 0.79, 95% CI 0.73-0.86, P < .001). For the matched pair, the median OS was 5.8 months with ChemoRT and 5.0 months with RT alone; the 2-year OS rate was 9% with ChemoRT and 4% with RT alone (P < .001). Concurrent chemotherapy has been administered with RT for the majority of elderly GBM patients. Addition of chemotherapy to RT for elderly GBM patients is associated with significantly improve OS in routine clinical practice.
Indexed as
Identifiers
27844308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.